Lumito (LUMITO) Q1 2026 earnings summary

Executive summary

• Achieved first commercial revenues with net sales of 78 TSEK in Q1 2026, marking transition from development to commercialization of SCIZYS platform.

• Strategic partnerships and pilot projects initiated with leading academic and industry players, including Atlas Antibodies, Offspring Biosciences, OracleBio, and Tethis.

• Patent protection expanded with approval in India, complementing existing coverage in Europe and the US.

• Structural changes implemented, including share consolidation and capital structure adjustments, to support future growth.

• First revenues from CRO partnerships realized post-period, validating the business model.

Financial highlights

• Net sales reached 78 TSEK in Q1 2026, compared to 0 TSEK in Q1 2025.

• Net loss after tax improved to -10,495 TSEK from -11,803 TSEK year-over-year.

• Operating loss was -10,226 TSEK, compared to -11,374 TSEK in Q1 2025.

• Cash flow from operations was -6,732 TSEK, nearly unchanged from -6,784 TSEK last year.

• Cash and cash equivalents at period end were 8,990 TSEK, down from 14,711 TSEK a year earlier.

Outlook and guidance

• Focus remains on converting pilot projects and partnerships into long-term commercial contracts.

• Continued expansion of the SCIZYS ecosystem and commercialization efforts expected to drive growth.

• Activities in Q1 2026 have laid the foundation for broader market acceptance and scaling.